Results 151 to 160 of about 36,270 (220)

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review. [PDF]

Hum Vaccin Immunother
Shono A, Hoshi SL, Kondo M.
europepmc   +1 more source

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children in Papua New Guinea, Lao PDR, and Mongolia. [PDF]

BMC Infect Dis
von Mollendorf C, Jagne I, Ashley EA, Blyth CC, Chan J, Ford RL, Mayxay M, Mulholland EK, Mungun T, Narangerel D, Tundev O, Nation ML, Nguyen CD, Ortika BD, Pell CL, Sapura J, Vilivong K, Lai J, Zhang Y, Dance DAB, Pomat WS, Satzke C, Russell FM, PneuCaPTIVE Research Group.   +23 more
europepmc   +1 more source

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan

, 2015
Shu‐ling Hoshi, Masahide Kondo, Ichiro Okubo   +2 more
openalex   +2 more sources

Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea. [PDF]

Hum Vaccin Immunother
Choe YJ, Jeon Y, Park J, Kim H, Yang G, Mohanty S, Floros L, Huang M, Chhabra N, Kumari S, Singh J, Sukarom I.   +11 more
europepmc   +1 more source

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants. [PDF]

Pediatr Infect Dis J
Pichon S, Ullery GM, Cousin L, Sadarangani M, Ryu JH, Monfredo C, Mari K, Pandey A, Personnic S, Pouzet C, Manson C, Silhadi W, Minutello AM.   +12 more
europepmc   +1 more source

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan

Miwa Haranaka, Joon Young Song, Kuo‐Chin Huang, Richard de Solom, Masako Yamaji, Kathleen McElwee, Mary Kline, Masakazu Aizawa, Yahong Peng, Ingrid L. Scully, Osamu Kogawara, William C. Gruber, Daniel A. Scott, Wendy Watson   +13 more
openalex   +1 more source

Potential clinical efficacy of the 10-valent pneumococcal-Protein D conjugate vaccine in children with chronic suppurative lung diseases: A double-blind randomised controlled trial [PDF]

, 2016
Kerry-Ann O’Grady, Keith Grimwood, Allan W. Cripps, E. Kim Mulholland, Heidi Smith‐Vaughan, Margie Danchin, Nicholas Wood, Andrew Wilson, Ruth B. Thornton, Paul J. Torzillo, Peter Morris, Peter Richmond, Kirsten P. Perrett, Sheree Rablin, Anne Connor, Vikas Goyal, Tanya Stoney, Anne B. Chang   +17 more
openalex  

Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era. [PDF]

Pediatr Blood Cancer
Yee ME, Abel L, Kalmus G, Patel A, Elmontser M, Bakshi N, Wang YF, Gonzalez MD, Adamkiewicz TV, Yildirim I, Lane PA.   +10 more
europepmc   +1 more source

Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review. [PDF]

Hum Vaccin Immunother
Yewale V, Chatterjee P, Marathe SM, Taur S, Sathyanarayanan S.   +4 more
europepmc   +1 more source

Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older [PDF]

Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith   +7 more
openalex   +1 more source